IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
02 oct. 2024 09h21 HE
|
IntelGenx Technologies Corp.
MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of...
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
19 juil. 2024 16h05 HE
|
IntelGenx Technologies Corp.
MONTREAL, July 19, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OTC: IGXT), a leading drug delivery company focused on the development and manufacturing of...
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
03 juil. 2024 08h00 HE
|
IntelGenx Technologies Corp.
MONTREAL, July 03, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), has successfully completed the BUENA...
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
11 juin 2024 08h52 HE
|
IntelGenx Technologies Corp.
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an...
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
28 mai 2024 10h05 HE
|
IntelGenx Technologies Corp.
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery...
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
17 mai 2024 17h39 HE
|
IntelGenx Technologies Corp.
MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and...
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
17 mai 2024 10h04 HE
|
IntelGenx Technologies Corp.
MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and...
IntelGenx Announces Voting Results on Election of Directors
08 mai 2024 07h45 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of...
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
08 avr. 2024 07h45 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm® has been administered to...
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
05 avr. 2024 07h45 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its...